Forbion’s ‘landmark’ €2.3B fundraise to benefit 30 ‘high potential’ biotechs

Forbion has touted its “landmark” 2.3 billion euro ($2.6 billion) fundraise across two funds as a new record for the European life sciences-focused VC firm.The cash, raised across the Forbion Growth Opportunities Fund IV and Forbion Ventures Fund VIII, will be used to support around 30 “high potential” biotechs, according to an Oct. 6 release.